Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease

被引:1
|
作者
Kim, Han-Kyeol [1 ]
Kim, Tae Won [1 ]
Baek, Min Seok [2 ]
Kim, Eung Yeop [3 ]
Sung, Young Hee [4 ]
Lee, Jae Hoon [5 ]
Ryu, Young Hoon [5 ]
Ahn, Sung Jun [6 ]
Yoo, Han Soo [1 ]
Lyoo, Chul Hyoung [1 ]
机构
[1] Yonsei Univ, Gangnam Severance Hosp, Dept Neurol, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Wonju Severance Christian Hosp, Dept Neurol, Wonju Coll Med, Wonju, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea
[4] Gachon Univ, Dept Neurol, Gil Med Ctr, Incheon, South Korea
[5] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Radiol, Seoul, South Korea
[6] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Nucl Med, Seoul, South Korea
关键词
dopamine transporter; nigrosome; 1; nigrostriatal degeneration; Parkinson's disease; SMwI; visual assessment; SUBSTANTIA-NIGRA; HUMAN BRAIN; DIAGNOSIS;
D O I
10.1111/ene.15781
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Nigrosome 1 (NG1), a small cluster of dopaminergic cells in the substantia nigra and visible in the susceptibility map-weighted magnetic resonance image (SMwI), is severely affected in Parkinson's disease (PD). However, the degree of nigrostriatal degeneration according to the visibility of NG1 has not yet been well elucidated.Methods We consecutively recruited 138 PD and 78 non-neurodegenerative disease (non-ND) patients, who underwent both F-18-FP-CIT positron emission tomography (PET) and SMwI. Three neurologists and one radiologist evaluated the visibility of NG1 in SMwI. The participants were thereby grouped into visible, intermediate, and non-visible groups. Nigrostriatal dopaminergic input was calculated using the specific binding ratio (SBR) of the F-18-FP-CIT PET. We determined the threshold of regional SBR for discriminating NG1 visibility and the probability for NG1 visibility according to regional SBR.Results Visual rating of NG1 showed excellent interobserver agreements as well as high sensitivity and specificity to differentiate the PD group from the non-ND group. NG1 was visible in seven patients (5.1%) in the PD group, who had relatively short disease duration or less severe loss of striatal dopamine. The threshold of putaminal SBR reduction on the more affected side for the disappearance of NG1 was 45.5%, and the probability for NG1 visibility dropped to 50% after the reduction of putaminal SBR to 41% from the normal mean.Conclusions Almost half loss of nigrostriatal dopaminergic input is required to dissipate the hyperintensity of NG1 on SMwI, suggesting its utility in diagnosing PD only after the onset of the motor symptoms.
引用
收藏
页码:1639 / 1647
页数:9
相关论文
共 50 条
  • [21] Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
    Isaias, Ioannis U.
    Trujillo, Paula
    Summers, Paul
    Marotta, Giorgio
    Mainardi, Luca
    Pezzoli, Gianni
    Zecca, Luigi
    Costa, Antonella
    FRONTIERS IN AGING NEUROSCIENCE, 2016, 8
  • [22] IMPAIRED FINGER DEXTERITY AND NIGROSTRIATAL DOPAMINE LOSS IN PARKINSON'S DISEASE
    Kim, J.
    Lee, M. S.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E15 - E15
  • [23] Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson’s disease
    S. H. Lee
    M. J. Lee
    C. H. Lyoo
    H. Cho
    M. S. Lee
    Journal of Neural Transmission, 2018, 125 : 1333 - 1339
  • [24] Oestrogen and nigrostriatal dopaminergic neurodegeneration: Animal models and clinical reports of Parkinson's disease
    Liu, Bin
    Dluzen, Dean E.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2007, 34 (07) : 555 - 565
  • [25] Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease
    Lee, S. H.
    Lee, M. J.
    Lyoo, C. H.
    Cho, H.
    Lee, M. S.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (09) : 1333 - 1339
  • [26] In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives:: Implications for Parkinson's Disease
    Abin-Carriquiry, J. Andres
    Costa, Gustavo
    Urbanavicius, Jessika
    Cassels, Bruce K.
    Rebolledo-Fuentes, Marco
    Wonnacott, Susan
    Dajas, Federico
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 589 (1-3) : 80 - 84
  • [27] Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease
    Muller, T
    Kuhn, W
    Buttner, T
    Eising, E
    Coenen, H
    Haas, M
    Przuntek, H
    JOURNAL OF NEUROLOGY, 1998, 245 (10) : 659 - 664
  • [28] Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson’s disease
    T. Müller
    Wilfried Kuhn
    Thomas Büttner
    Ernst Eising
    H. Coenen
    Martin Haas
    Horst Przuntek
    Journal of Neurology, 1998, 245 : 659 - 664
  • [29] Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease
    Sano, Hiromi
    Murata, Miho
    Nambu, Atsushi
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 (02) : 371 - 381
  • [30] Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease
    Ouchi, Y
    Kanno, T
    Okada, H
    Yoshikawa, E
    Futatsubashi, M
    Nobezawa, S
    Torizuka, T
    Tanaka, K
    BRAIN, 2001, 124 : 784 - 792